Skip to main content
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: J Neurochem. 2014 Aug 6;131(4):521–529. doi: 10.1111/jnc.12824

Figure 5.

Figure 5

Treatment of BMECs with GTPCH-I siRNA suppressed bioavailability of BH4 and endothelial NO. A) Exposure of BMECs to GTPCH-I siRNA resulted in significantly attenuated expression of GTPCH-I (* P<0.05 vs. Control siRNA-treated BMECs, n=4). (B) Ratio of BH4 to 7,8-BH2 was significantly reduced in BMECs treated with GTPCH-I siRNA (*P<0.05, n=5). Reduced bioavailability of BH4 was associated with increased production of superoxide anions (C, *P<0.05, n=7) and reduced bioavailability of NO (D, * P<0.05, n=5).